fundno affsans résumé
Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT2018· article· en· European Journal of Pharmacology· Medicine
66
citations